Drug resistance and the solid tumor microenvironment

Journal of the National Cancer Institute

Volumn 99, Issue 19, 2007, Pages 1441-1454

  Trédan, Olivier ^a   Galmarini, Carlos M ^b   Patel, Krupa ^a   Tannock, Ian F ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITÉ LYON 1   (France)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BOTULINUM TOXIN A; BRADYKININ RECEPTOR AGONIST; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; COMBRETASTATIN A4; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENDOTHELIN RECEPTOR ANTAGONIST; EPIRUBICIN; FLUOROURACIL; HYDRALAZINE; IMATINIB; MITOFLAXONE; MITOXANTRONE; PACLITAXEL; TIRAPAZAMINE; TOPOTECAN; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ACIDITY; ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL INTERACTION; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; EXTRACELLULAR MATRIX; HUMAN; HYPOXIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NONHUMAN; PRESSURE GRADIENT; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SOLID TUMOR; TISSUE DISTRIBUTION; TISSUE PRESSURE; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR MODEL; TUMOR RESISTANCE; TUMOR VASCULARIZATION; ANIMAL; CELL HYPOXIA; DRUG RESISTANCE; METABOLISM; MICROCIRCULATION; NEOPLASM; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; HUMANS; MICROCIRCULATION; NEOPLASMS;

EID: 35148881028     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm135     Document Type: Review

References (176)

1. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
2. Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990;247:1457-61.
3. Kerbel RS, St Croix B, Florenes VA, Rak J. Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum Cell 1996;9:257-64.
4. Aznavoorian S, Stracke ML, Krutzsch HC, Schiffmann E, Liotta LA. Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol 1990;110:1427-38.
5. Ohtani H. Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol Int 1998; 48:1-9.
6. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science 1998;280:1036-7.
7. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
8. Roskelley CD, Bissell MJ. The dominance of microenvironment in breast and ovarian cancer. Semin Cancer Biol 2002;12:97-104.
9. Brekken C, Bruland OS, de Lange DC. Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase. Anticancer Res 2000; 20:3503-12.
10. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-503.
11. Durand RE. Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment. J Natl Cancer Inst 1986;77:247-52.
12. Olive PL, Durand RE. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev 1994;13:121-38.
13. Galmarini FC, Galmarini CM, Sarchi MI, Abulafia J, Galmarini D. Heterogeneous distribution of tumor blood supply affects the response to chemotherapy in patients with head and neck cancer. Microcirculation 2000;7:405-10.
14. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:2641-58.
15. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65.
16. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
17. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80.
18. Stewart PA, Hayakawa K, Farrell CL, Del Maestro RF. Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. J Neurosurg 1987;67:697-705.
19. Yonenaga Y, Mori A, Onodera H, Yasuda S, Oe H, Fujimoto A, et al. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 2005;69:159-66.
20. Sevick EM, Jain RK. Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 1989;49:3506-12.
21. Sevick EM, Jain RK. Effect of red blood cell rigidity on tumor blood flow: increase in viscous resistance during hyperglycemia. Cancer Res 1991;51:2727-30.
22. Padera TP, Stoll BR, Tooredman JB. Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 2004; 427:695.
23. Gillies RJ, Schornack PA, Secomb TW, Raghunand N. Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1999;1:197-207.
24. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49:4373-84.
25. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: simultaneous high-resolution measurements reveal a lack of correlation. Nat Med 1997;3:177-82.
26. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757.
27. Durand RE. Intermittent blood flow in solid tumours-an under-appreciated source of "drug resistance". Cancer Metastasis Rev 2001;20:57-61.
28. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000;60:4324-7.
29. Milosevic MF, Fyles AW, Wong R, Pintilie M, Kavanagh MC, Levin W, et al. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer 1998;82: 2418-26.
30. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000;60:4251-5.
31. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13.
32. Netti PA, Hamberg LM, Babich JW, Kierstead D, Graham W, Hunter GJ, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci USA 1999;96: 3137-42.
33. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, et al. Role of tumor-host interactions in interstitial diffusion of macro- molecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 2001;98:4628-33.
34. Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J 2003;17:1756-8.
35. Dewhirst MW, Klitzman B, Braun RD, Brizel DM, Haroon ZA, Secomb TW. Review of methods used to study oxygen transport at the microcir- culatory level. Int J Cancer 2000;90:237-55.
36. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680-7.
37. Milosevic M, Fyles A, Hedley D, Hill R. The human tumor microenviron- ment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004;14:249-58.
38. Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, Zhang P, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 2000;60:2018-24.
39. Bussink JKJ, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003;67:3-15.
40. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006;24:727-35.
41. Tannock IF. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer 1968;22:258-73.
42. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
43. Chaplin DJ, Trotter MJ, Durand RE, Olive PL, Minchinton AI. Evidence for intermittent radiobiological hypoxia in experimental tumour systems. Biomed Biochim Acta 1989;48:S255-9.
44. Durand RE, LePard NE. Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncol 1995;34:317-23.
45. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
46. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
47. Hirst DG, Denekamp J. Tumour cell proliferation in relation to the vas- culature. Cell Tissue Kinet 1979;12:31-42.
48. Ljungkvist AS, Bussink J, Rijken PF, Kaanders JH, van der Kogel AJ, Denekamp J. Vascular architecture, hypoxia J. proliferation in first- generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2002;54:215-28.
49. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 1978;62:1117-33.
50. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19:4319-27.
51. Shain KH, Dalton WS. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 2001;1:69-78.
52. Guo YS, Jin GF, Houston CW, Thompson JC, Townsend CM Jr. Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. J Cell Physiol 1998;175:141-8.
53. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;662-8.
54. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002;2:205-16.
55. Damiano JS. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets 2002;2:37-43.
56. Wang GL, Semenza GL. Purification and characterization of hypoxia- inducible factor 1. J Biol Chem 1995;270:1230-7.
57. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441:437-43.
58. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
59. Kinoshita M, Johnson DL, Shatney CH, Lee YL, Mochizuki H. Cancer cells surviving hypoxia obtain hypoxia resistance and maintain anti- apoptotic potential under reoxygenation. Int J Cancer 2001;91:322-6.
60. Kondo A, Safaei R, Mishima M, Niedner H, Lin X, Howell SB. Hypoxia- induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res 2001;61:7603-7.
61. Rice GC, Hoy C, Schimke RT. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci USA 1986;83:5978-82.
62. Rice GC, Ling V, Schimke RT. Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance. Proc Natl Acad Sci USA 1987;84:9261-4.
63. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387-94.
64. Tomida A, Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 1999; 14:169-77.
65. Shen J, Hughes C, Chao C, Cai J, Bartels C, Gessner T, et al. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci USA 1987;84:3278-82.
66. Yun J, Tomida A, Nagata K, Tsuruo T. Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol Res 1995;7:583-90.
67. Gray MD, Mann M, Nitiss JL, Hendershot LM. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs. Mol Pharmacol 2005;68:1699-707.
68. Ledoux S, Yang R, Friedlander G, Laouari D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticu- lum stress response. Cancer Res 2003;63:7284-90.
69. Kovacic P, Osuna JA Jr. Mechanisms of anti-cancer agents: emphasis on oxidative stress and electron transfer. Curr Pharm Des 2000;6:277-309.
70. Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 2001; 8:739-61.
71. Kennedy KA Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des 1987;2:181-94.
72. Rockwell S. Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Int J Cancer 1986; 38:229-35.
73. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
74. Gerrweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther 2006; 5:1275-9.
75. Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 1999;80:1005-11.
76. Raghunand N, Mahoney BP, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemo- therapeutic agents. Biochem Pharmacol 2003;66:1219-29.
77. Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 2003;66:1207-18.
78. Cowan DS, Tannock IF. Factors that influence the penetration of methotrexate through solid tissue. Int J Cancer 2001;91:120-5.
79. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92.
80. Di Paolo A, Bocci G. Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. Curr Oncol Rep 2007;9:109-14.
81. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814s-9s.
82. DiResta GR, Lee J, Larson SM, Arbit E. Characterization of neuroblastoma xenograft in rat flank. I. Growth, interstitial fluid pressure, and interstitial fluid velocity distribution profiles. Microvasc Res 1993;46:158-77.
83. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 1995;55:5451-8.
84. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromo- lecular drug carriers. J Natl Cancer Inst 2006;98:335-44.
85. Curti BD, Urba WJ, Alvord WG, Janik JE, Smith JW 2nd, Madara K, et al. Interstitial pressure of subcutaneous nodules in melanoma and lym- phoma patients: changes during treatment. Cancer Res 1993;53:2204-7.
86. Herrera FG, Chan P, Doll C, Milosevic M, Oza A, Syed A, et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys 2007;67:97-103.
87. Davies Cde L, Berk DA, Pluen A, Jain RK. Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br J Cancer 2002;86:1639-44.
88. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 1999;290:871-80.
89. Au JL, Jang SH, Wientjes MG. Clinical aspects of drug delivery to tumors. J Control Release 2002;78:81-95.
90. Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 2006;66:1033-9.
91. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue- isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990;50:4478-84.
92. Berk DA, Yuan F, Leunig M, Jain RK. Direct in vivo measurement of targeted binding in a human tumor xenograft. Proc Natl Acad Sci USA 1997;94:1785-90.
93. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31:1191-8.
94. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992; 52:5144-53.
95. Coley HM, Amos WB, Twentyman PR, Workman P. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellu- lar localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer 1993;67:1316-23.
96. Lee CM, Tannock IF. Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer 2006;94:863-9.
97. Kerr DJ, Kaye SB. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol 1987;19:1-5.
98. Kyle AH, Huxham LA, Chiam AS, Sim DH, Minchinton AI. Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture. Cancer Res 2004;64:6304-9.
99. Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D. Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 1979;5:1225-30.
100. Durand RE. Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? Cancer Chemother Pharmacol 1990;26:198-204.
101. West GW, Weichselbaum R, Little JB. Limited penetration of metho- trexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 1980;40:3665-8.
102. Wibe E. Resistance to vincristine of human cells grown as multicellular spheroids. Br J Cancer 1980;42:937-41.
103. Nederman T, Carlsson J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 1984;13:131-5.
104. Tunggal JK, Cowan DS, Shaikh H, Tannock IF. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res 1999;5:1583-6.
105. Hicks KO, Fleming Y, Siim BG, Koch CJ, Wilson WR. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys 1998;42:641-9.
106. Hicks KO, Pruijn FB, Baguley BC, Wilson WR. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)- ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells. J Pharmacol Exp Ther 2001;297:1088-98.
107. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8:878-84.
108. Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 2006;98:1118-28.
109. Lankelma J, Dekker H, Luque FR, Luykx S, Hoekman K, van der Valk P, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999;5:1703-7.
110. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005;11:8782-8.
111. Huxham LA, Kyle AH, Baker JH, Nykilchuk LK, Minchinton AI. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 2004;64:6537-41.
112. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
113. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
114. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005;5:516-25.
115. Brade AM, Tannock IF. Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure?. J Clin Oncol 2006;24:1020-2.
116. Miyamoto T, Ishii S, Eguchi-Kasai K, Koyama-Saegusa K. Radiosensitivity of hypoxic and proliferating clonogen in a human lung cancer grown in nude mice. Oncol Rep 2005;14:1421-8.
117. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
118. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
119. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
120. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165:35-52.
121. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
122. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88:1979-86.
123. Segers J, Fazio VD, Ansiaux R, Martinive P, Feron O, Wallemacq P, et al. Potentiation of cyclophosphamide chemotherapy using the anti- angiogenic drug thalidomide: importance of optimal scheduling to exploit the "normalization" window of the tumor vasculature. Cancer Lett 2006;244:129-35.
124. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
125. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
126. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
127. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, et al. Surrogate markers for antiangiogenic therapy and dose-limiting tox- icities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-9.
128. Horsman MR, Siemann DW. Pathophysiologic effects of vascular- targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;24:11520-39.
129. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
130. Batchelor TT. Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
131. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
132. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF- induced vascular permeability. Nature 2005;437:497-504.
133. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 2006; 66:1434-45.
134. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-64.
135. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006;66:3639-48.
136. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110:475-82.
137. Morinaga Y, Suga Y, Ehara S, Harada K, Nihei Y, Suzuki M. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 2003;94:200-4.
138. Brunstein F, Rens J, van Tiel ST, Eggermont AM, ten Hagen TL. Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery. Br J Cancer 2006;95:1663-9.
139. Sonveaux P, Dessy C, Martinive P, Havaux X, Jordan BF, Gallez B, et al. Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res 2004;64:3209-14.
140. Martinive P, Defresne F, Bouzin C, Saliez J, Lair F, Gregoire V, et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 2006;66: 11736-44.
141. Ansiaux R, Baudelet C, Cron GO, Segers J, Dessy C, Martinive P, et al. Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin Cancer Res 2006;12:1276-83.
142. Kristjansen PE, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res 1993;53:4764-6.
143. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane- induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999;59: 3776-82.
144. Jang SH, Wientjes MG, Au JL. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther 2001;296:1035-42.
145. Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoad- juvant chemotherapy: clinical implications. J Clin Oncol 2005; 23:1951-61.
146. Hirst DG, Hirst VK, Shaffi KM, Prise VE, Joiner B. The influence of vasoactive agents on the perfusion of tumours growing in three sites in the mouse. Int J Radiat Biol 1991;60:211-8.
147. Zlotecki RA, Baxter LT, Boucher Y, Jain RK. Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. Microvasc Res 1995;50:429-43.
148. Rubin K, Sjoquist M, Gustafsson AM, Isaksson B, Salvessen G, Reed RK. Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralleled by an increased uptake of (51)Cr-EDTA. Int J Cancer 2000;86:636-43.
149. Emerich DF, Dean RL, Snodgrass P, Lafreniere D, Agostino M, Wiens T, et al. Bradykinin modulation of tumor vasculature: II. activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J Pharmacol Exp Ther 2001;296:632-41.
150. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62: 5476-84.
151. Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003;9: 3779-87.
152. Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005;23:973-81.
153. Tunggal JK, Melo T, Ballinger JR, Tannock IF. The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int J Cancer 2000;86:101-7.
154. Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 1994;12:1771-7.
155. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, et al. A phase III randomized study of oral verapamil as a chemosen- sitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 1995;75:815-20.
156. Kozin SV, Shkarin P, Gerweck LE. The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res 2001;61:4740-3.
157. Raghunand N, Mahoney B, van Sluis R, Baggett B, Gillies RJ. Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone. Neoplasia 2001;3:227-35.
158. Eikenes L, Bruland OS, Brekken C, Davies Cde L. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res 2004;64:4768-73.
159. Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 2003;9:796-800.
160. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluo- rouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French inter- group study. J Clin Oncol 1997;15:808-15.
161. O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, et al. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule-an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B study. J Clin Oncol 2001;19:2413-21.
162. Di Paolo A. Liposomal anticancer therapy: pharmacokinetic and clinical aspects. J Chemother 2004;16 Suppl 4:90-3.
163. Tang N, Du G, Wang N, Liu C, Hang H, Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 2007;99:1004-15.
164. Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006;8:39-45.
165. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986;12:12 3 9-42.
166. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 2000; 18:1351-9.
167. Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DH, Tucker RW, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005;23: 9097-104.
168. Kyle AH, Minchinton AI. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 1999;43:213-20.
169. Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 2003;63:5970-7.
170. th American Association for Cancer Research Annual Meeting; 2006 April 1-5; Washington (DC); Abstract 2414.
171. th American Association for Cancer Research Annual Meeting; 2007 April 14-18; Los Angeles, CA; Abstract 5736.
172. Moese JR, Moese G. Oncolysis by clostridia. I. Activity of clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res 1964;24:212-6.
173. Agrawal N, Bettegowda C, Cheong I, Geschwind JF, Drake CG, Hipkiss EL, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci USA 2004;101:15172-7.
174. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001;98:15155-60.
175. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of sys- temically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 2002;9:291-6.
176. Cheong I, Huang X, Bettegowda C, Diaz LA Jr, Kinzler KW, Zhou S, et al. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 2006;314:1308-11.